189 filings
Page 2 of 10
6-K
g7rq 90lf
10 Mar 23
Current report (foreign)
5:06pm
6-K
ep03wi93v73t
26 Jan 23
Current report (foreign)
7:05am
6-K
lzziw2 phouo
30 Nov 22
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
7:09am
6-K
h7whtq04d2c5c7
28 Oct 22
Current report (foreign)
8:00am
6-K
bkr92tvfe
26 Sep 22
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
9:07am
6-K
1ru47i2srqcfjmn yft
2 Aug 22
Detailed data from the phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
11:12am
6-K
mi0 qd9vm31pq4
28 Jul 22
Current report (foreign)
7:36am
6-K
ko0s3
24 Jun 22
Current report (foreign)
5:29pm
6-K
7y1du7s846k n2lb3t
16 Jun 22
AC Immune provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
7:38am
6-K
kzcj4tczm7o4m
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
424B5
umgwh
19 May 22
Prospectus supplement for primary offering
7:22am
6-K
nr7ia5ovj
28 Apr 22
Current report (foreign)
7:37am
6-K
eoujixzw9dyxo9n
8 Apr 22
AC Immune Reports Changes to Senior Management
7:36am
6-K
ppml aw8m
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
6-K
zpz0j6hu9
16 Mar 22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
7:51am
6-K
9u57v6yssjff
12 Nov 21
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
9:27am
6-K
7xc8oa85i7sfi3860
8 Nov 21
Current report (foreign)
7:27am
6-K
2qxp6 1pg
29 Oct 21
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
4:35pm